Bio Blast Pharma (ORPN) Surged On Positive Phase 2 Study News

Bio Blast Pharma Ltd. (ORPN) announced positive results from its HOPEMD Phase 2 clinical study in patients with oculopharyngeal muscular dystrophy.

from RTT - Before the Bell http://ift.tt/1PdzM2X
via IFTTT